MBIO Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Mustang Bio's net margin of --. Mustang Bio's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 8096.72%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 502.21%. Given that Mustang Bio has higher upside potential than Perspective Therapeutics, analysts believe Mustang Bio is more attractive than Perspective Therapeutics.

Mustang Bio has a beta of 2.143, which suggesting that the stock is 114.262% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Mustang Bio's net income of -$1.4M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Mustang Bio's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 15.47x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to Mustang Bio's net margin of 12.11%. Mustang Bio's return on equity of -- beat Electromed's return on equity of 15.91%.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 8096.72%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 60.45%. Given that Mustang Bio has higher upside potential than Electromed, analysts believe Mustang Bio is more attractive than Electromed.

Mustang Bio has a beta of 2.143, which suggesting that the stock is 114.262% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Mustang Bio's net income of -$1.4M is lower than Electromed's net income of $2M. Notably, Mustang Bio's price-to-earnings ratio is -- while Electromed's PE ratio is 30.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 3.46x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Fortress Biotech has a net margin of -- compared to Mustang Bio's net margin of -87.96%. Mustang Bio's return on equity of -- beat Fortress Biotech's return on equity of --.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 8096.72%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 834.96%. Given that Mustang Bio has higher upside potential than Fortress Biotech, analysts believe Mustang Bio is more attractive than Fortress Biotech.

Mustang Bio has a beta of 2.143, which suggesting that the stock is 114.262% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.825, suggesting its more volatile than the S&P 500 by 82.547%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Mustang Bio's net income of -$1.4M is higher than Fortress Biotech's net income of -$12.9M. Notably, Mustang Bio's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 0.46x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Mustang Bio's net margin of 35.65%. Mustang Bio's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 8096.72%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 408.77%. Given that Mustang Bio has higher upside potential than Protalix BioTherapeutics, analysts believe Mustang Bio is more attractive than Protalix BioTherapeutics.

Mustang Bio has a beta of 2.143, which suggesting that the stock is 114.262% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Mustang Bio's net income of -$1.4M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Mustang Bio's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 95.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 4.43x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.